|
nasopharyngeal carcinoma |
21 |
|
chemotherapy |
12 |
|
radiotherapy |
10 |
|
medical sciences |
9 |
|
plasma ebv dna |
9 |
|
recursive partitioning analysis |
9 |
|
stage classification |
9 |
|
survival prediction |
9 |
|
chinese |
8 |
|
nomogram |
8 |
|
non-small-cell lung cancer |
8 |
|
oncology |
8 |
|
survival |
8 |
|
epidermal growth factor receptor |
7 |
|
prognostic factors |
7 |
|
tyrosine kinase inhibitors |
7 |
|
cetuximab |
6 |
|
dosimetric predictors |
6 |
|
hypothyroidism |
6 |
|
intensity-modulated radiation therapy |
6 |
|
5-fluorouracil |
5 |
|
capecitabine |
5 |
|
metastatic |
5 |
|
metastatic colorectal cancer |
5 |
|
metronomic |
5 |
|
oral cyclophosphamide |
5 |
|
recurrent |
5 |
|
acceptance |
4 |
|
anxiety |
4 |
|
assessment |
4 |
|
cancer |
4 |
|
covid-19 |
4 |
|
cytology and histology |
4 |
|
high dose rate endorectal brachytherapy |
4 |
|
medically inoperable |
4 |
|
oncology medical sciences |
4 |
|
palliative care |
4 |
|
prediction |
4 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
4 |
|
rectal brachytherapy |
4 |
|
rectal cancer |
4 |
|
toxicities |
4 |
|
toxicity |
4 |
|
treatment |
4 |
|
vaccination |
4 |
|
accuracy |
3 |
|
active surveillance |
3 |
|
advanced cancer |
3 |
|
bevacizumab |
3 |
|
do-not-resuscitate |
3 |
|
end of life |
3 |
|
esophageal cancer |
3 |
|
esophagectomy |
3 |
|
kras wild-type |
3 |
|
metastatic colorectal carcinoma |
3 |
|
neoadjuvant chemoradiotherapy |
3 |
|
communication |
2 |
|
conditional survival |
2 |
|
cytokine |
2 |
|
lung dosimetric factors |
2 |
|
non-small cell lung cancer |
2 |
|
radiation esophagitis |
2 |
|
radiation-induced lung fibrosis |
2 |
|
support vector machine |
2 |
|
terminal care |
2 |
|
chemotherapy, adjuvant |
1 |
|
colorectal neoplasms |
1 |
|
receptor, epidermal growth factor |
1 |
|
vascular epidermal growth factor |
1 |
